Might we see generic abiraterone acetate this year?

On Wednesday the U.S. Patent Trial and Appeal Board invalidated the last remaining patent on abiraterone acetate (Zytiga), making it possible that generic forms of abiraterone acetate would be available in 2018 (at least in the US). … READ MORE …

What did the patient actually die of?

Two questions that come up regularly are whether: (a) men who are said to have died of prostate cancer actually did, and (b) men with prostate cancer who are said to have died of something else actually died of their prostate cancer. … READ MORE …

Molecular biological reasons for switching to a healthier diet!

Two articles just published this week by a Boston-based research team have implicated Western high-fat diets in risk for metastasis of prostate cancer. … READ MORE …

Ac-225-PSMA-617 in mCRPC: an update

We now have some details from clinical trials of the radiopharmaceutical actinium-225-PSMA-617 (Ac-225-PSMA-617) in very advanced prostate cancer patients. … READ MORE …

Your genetics can accurately predict your age-related prostate cancer risk

Data from a new study reported in the British Medical Journal discusses a “polygenic hazard score” that can potentially be used to guide screening for aggressive prostate cancer (but only in men of European ancestry at this time). … READ MORE …

Low PSA levels on ADT do correlate to longer survival times

For many years now, people have asked whether specific PSA levels after initiation of androgen deprivation therapy (ADT, also known as “hormone therapy”)  have significant predictive impact on long-term survival. … READ MORE …

PET/MRI scanning in pre-surgical staging of high-risk prostate cancer patients

A small, Norwegian, Phase II clinical trial has explored the potential diagnostic value of [18F]fluciclovine PET/MRI scans of the pelvic lymph nodes in staging for patients with high-risk prostate cancer. … READ MORE …